A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients

Annals of Plastic Surgery

Volumn 68, Issue 1, 2012, Pages 22-28

  Armendariz Borunda, Juan ^a,b   Lyra Gonzalez, Ivan ^a   Medina Preciado, David ^b   Gonzalez García, Ignacio ^b   Martinez Fong, Daniel ^c   Miranda, Rodolfo Ariel ^b   Magaña Castro, Rogelio ^d   Peña Santoyo, Pedro ^d   Garcia Rocha, Sergio ^b   Bautista, Carlos Alfredo ^b   Godoy, Jesus ^b   Flores Montana, Jesus ^e   Floresvillar Mosqueda, Jorge ^a   Armendariz Vazquez, Oscar ^a   Lucano Landeros, Martha Silvia ^a   Vazquez Del Mercado, Monica ^a   Sanchez Parada, Maria G ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d SA de CV   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA   (Mexico)

Author keywords

burn scars; burns; pathological skin scarring; pediatric bur; Pirfenidone; scar; scar regression; Vancouver Scar Scale

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE;

ADOLESCENT; ARTICLE; BURN; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPRESSION BANDAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; GEL; HUMAN; HYPERTROPHIC SCAR; INTRADERMAL DRUG ADMINISTRATION; MALE; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BURNS; CHILD; CHILD, PRESCHOOL; CICATRIX, HYPERTROPHIC; COMPRESSION BANDAGES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GELS; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDONES; TREATMENT OUTCOME;

EID: 84855202918     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31821b6d08     Document Type: Article

References (52)

1. Alster TS, Tanzi EL. Hypertrophic scars and keloids. Etiology and management. Am J Clin Dermatol. 2003;4:235-243. (Pubitemid 36506429)
2. Peacock Jr EE, Madden JW, Trier WC. Biologic basis for the treatment of keloids and hypertophic scars. South Med J. 1970;63:755-760.
3. Ardehali B, Nouraei SA, Van Dam H, et al. Objective assessment of keloid scars with three-dimensional imaging: quantifying response to intralesional steroid therapy. Plast Reconstr Surg. 2007;119:556-561. (Pubitemid 46142941)
4. Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ. 2003;326: 88-92. (Pubitemid 36092292)
5. Al-Attar A, Mess S, Thomassen JM, et al. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006;117:286-300. (Pubitemid 44391579)
6. Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars. A meta-analysis and review of the Literature. Arch Facial Plast Surg. 2006;8:362-268.
7. Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J R Soc Interface. 2007;4:413-437.
8. Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J Am Coll Surg. 2008;206:731-741.
9. Babovic-Vuksanovic D, Widemann BC, Dombi E, et al. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol. 2007;36:293-300. (Pubitemid 46726967)
10. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med. 1999;159:1061-1069.
11. Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16.
12. Gancedo M, Ruiz-Corro L, Salazar-Montes A, et al. Pirfenidone prevents capsular contracture after mammary implantation. Aesth Plast Surg. 2008;32:32-40.
13. Hirano A, Kenehiro A, Ono K, et al. Perfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol. 2006;35:366-377. (Pubitemid 44353405)
14. Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 1998;54:99-109. (Pubitemid 28288024)
15. Byung-Seok L, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83:219-223. (Pubitemid 28498339)
16. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367-373. (Pubitemid 29451612)
17. Nathan SD. Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. Clin Chest Med. 2006;27:S27-S35.
18. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2005;55:1663-1665.
19. Nguyen DT, Ding C, Wilson E, et al. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010;7:1438-1445.
20. Sullivan T, Smith J, Kermode J, et al. Rating the burn scar. J Burn Care Rehabil. 1990;11:256-260.
21. Nedelec B, Shankowsky A, Tredgett EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil. 2000;21:205-212. (Pubitemid 30396350)
22. Lye I, Edgar DW, Wood FM, et al. Tissue tonometry is a simple, objective measure for pliability of burn scar: is it reliable? J Burn Care Res. 2006;27: 82-85. (Pubitemid 43970345)
23. Duncan JA, Bond JS, Mason T, et al. Visual analogue scale scoring and ranking: a suitable and sensitive method for assessing scar quality? Plast Reconstr Surg. 2006;118:909-918. (Pubitemid 44412923)
24. Durani P, McGrouther DA, Ferguson MW. Current scales for assessing human scarring: a review. J Plast Reconstr Aesthet Surg. 2009;62:713-720.
25. Micomonaco DC, Fung K, Mount G, et al. Development of a new visual analogue scale for the assessment of area scars. J Otolaryngol Head Neck Surg. 2009;38:77-89.
26. Daniel T, Thobe BM, Chaudhry IH, et al. Regulation of the postburn wound inflammatory response by γδ T-cells. Shock. 2007;28:278-283. (Pubitemid 47282018)
27. Rawlins JM, Lam WL, Karoo RO, et al. Quantifying collagen type in mature burn scars: a novel approach using histology and digital image analysis. J Burn Care Res. 2006;27:60-65. (Pubitemid 43970343)
28. Harte D, Gordon J, Shaw M, et al. The use of pressure and silicone in hypertrophic scar management in burns patients: a pilot randomized controlled trial. J Burn Care Res. 2009;30:632-642.
29. Groce A, Herndon DN, McCauley RL, et al. The effects of pressure versus no pressure garments in the control of hypertrophic scarring in children with small burns: a preliminary 6 months report. J Burn Care Rehabil. 2000;2:178.
30. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg. 2008;206:719-730.
31. Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol. 2006;55:1024-1031. (Pubitemid 44716469)
32. Guix B, Henriquez I, Andres A, et al. Treatment of keloids by high-dose-rate brachytherapy: a seven-year study. Int J Radiat Oncol Biol Phys. 2001;50: 167-172.
33. Ferguson MW, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebocontrolled, phase I/II studies. Lancet. 2009;373:1264-1274.
34. Stewart CE IV, Kim JY. Application of mitomycin-C for head and neck keloids. Otolaryngol Head Neck Surg. 2006;135:946-950. (Pubitemid 44820604)
35. Simman R, Alani H, Williams F. Effect of mitomycin C on keloid fibroblasts: an in vivo study. Ann Plast Surg. 2003;50:71-76. (Pubitemid 36070232)
36. Gragani A, Warde M, Furtado F, et al. Topical tamoxifen therapy in hypertrophic scars and keloids in burns. Arch Dermatol Res. 2010;302:1-4.
37. Onwukwe MF. Treating keloids by surgery and methotrexate. Arch Dermatol. 1980;116:158. (Pubitemid 10176558)
38. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002;47:S209-S211.
39. Caçaõ FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg. 2009; 35:629-633.
40. Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol. 1988;14:1275-1276. (Pubitemid 19000514)
41. Ong CT, Khoo YT, Mukhopadhyay A, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. 2007;16: 394-404. (Pubitemid 46585367)
42. D'Andrea F, Brongo S, Ferraro G, et al. Prevention and treatment of keloids with intralesional verapamil. Dermatology. 2002;204:60-62. (Pubitemid 34136816)
43. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg. 2009;124:275e-277e.
44. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33:409-412.
45. Zhang GY, Yi CG, Li X, et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res. 2008;300:177-184.
46. Ono I, Akasaka Y, Kikuchi R, et al. Basic fibroblast growth factor reduces scar formation in acute incisional wounds. Wound Repair Regen. 2007;15: 617-623. (Pubitemid 47493894)
47. Ono I, Yamashita T, Hida T, et al. Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. J Surg Res. 2004;120:47-55. (Pubitemid 38686529)
48. A double blind, placebo controlled trial to investigate the efficacy and safety of two concentrations of Juvidex (mannose-6-phosphate) in accelerating the healing of split thickness skin graft donor sites using different dosing regimes. ClinicalTrials.gov Identifier: NCT00664352. Available at: http://clinicaltrials.gov/NCT00664352. Accessed February 18, 2010.
49. Peranteau WH, Zhang L, Muvarak N, et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol. 2008;128:1852-1860. (Pubitemid 351847365)
50. Robson MC. Proliferative scarring. Surg Clin North Am. 2003;83:557-569. (Pubitemid 36687714)
51. Topol BM, Lewis VL Jr, Benveniste K. The use of antihistamine to retard the growth of fibroblasts derived from human skin, scar, and keloid. Plast Reconstr Surg. 1981;68:227-232. (Pubitemid 11044150)
52. Sandulache VC, Parekh A, Li-Korotky H, et al. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen. 2007;15:122-133. (Pubitemid 46150985)